Page last updated: 2024-09-05

sorafenib and apatinib

sorafenib has been researched along with apatinib in 8 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(apatinib)
Trials
(apatinib)
Recent Studies (post-2010) (apatinib)
6,5207305,251575109544

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)apatinib (IC50)
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.001

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (37.50)24.3611
2020's5 (62.50)2.80

Authors

AuthorsStudies
Duo, J; Ma, X; Zhao, Y; Zhu, H1
Han, Z; He, Z; Wang, C; Wang, Q1
Du, Y; Kong, L; Liang, Q; Tian, J; Zhu, X1
Hu, Y; Wu, L; Ye, Z; Zhang, X; Zheng, L1
Cao, Y; Chen, L; Kan, X; Liang, B; Ouyang, T; Xiong, F; Zheng, C1
Dai, JY; Jiang, B; Liu, KC; Lu, D; Lv, WF; Tan, YL; Wang, GX; Yin, L; Zhu, XH1
Bai, Y; Chan, SL; Chen, C; Chen, Y; Chen, Z; Cheng, AL; Cheng, Y; Gu, S; Guo, Y; Hu, X; Jia, W; Jin, Y; Kaseb, A; Li, W; Liang, J; Liang, X; Lin, X; Melisi, D; Meng, Z; Osypchuk, Y; Pazgan-Simon, M; Pisetska, M; Ponomarenko, D; Qin, S; Ren, H; Ren, Z; Sinielnikov, I; Sultanbaev, A; Vogel, A; Wang, L; Xiong, J; Yang, F; Yang, TS; Zeng, Y1
Chen, D; Chen, X; Kang, M; Wang, Y; Zhu, L1

Trials

1 trial(s) available for sorafenib and apatinib

ArticleYear
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
    Lancet (London, England), 2023, 09-30, Volume: 402, Issue:10408

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib

2023

Other Studies

7 other study(ies) available for sorafenib and apatinib

ArticleYear
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
    Medicine, 2018, Volume: 97, Issue:25

    Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed

2018
The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report.
    Medicine, 2018, Volume: 97, Issue:49

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Pyridines; Sorafenib

2018
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
    Experimental & molecular medicine, 2019, 07-08, Volume: 51, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Imaging; Molecular Targeted Therapy; Multimorbidity; Protein Kinase Inhibitors; Pyridines; Sorafenib

2019
Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS.
    Journal of pharmaceutical and biomedical analysis, 2021, Aug-05, Volume: 202

    Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Monitoring; Humans; Liver Neoplasms; Pharmaceutical Preparations; Phenylurea Compounds; Pyridines; Quinolines; Reproducibility of Results; Sorafenib; Tandem Mass Spectrometry

2021
Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
    Hepatology international, 2021, Volume: 15, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2021
Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2023, May-30, Volume: 23, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Propensity Score; Retrospective Studies; Sorafenib

2023
Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study.
    Scientific reports, 2023, 08-16, Volume: 13, Issue:1

    Topics: Body Weight; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib

2023